Clinical Studies

Nuvaira is committed to conducting rigorous clinical studies that help advance medical care for patients with obstructive lung diseases. Detailed information regarding all Nuvaira clinical studies can be found at

Current Clinical Studies:

AIRFLOW Clinical Study (NCT02058459)  – Enrollment Completed

Patient Population Moderate to severe COPD (chronic obstructive pulmonary disease)
Design This is a multi-center, interventional clinical trial.
Study Phase Phase 2
Study Goals The goal of the phased AIRFLOW clinical study is:
AIRFLOW-1: to compare two energy doses to select the optimal energy and confirm safety and feasibility.

AIRFLOW-2: to compare outcomes between the optimal energy dose vs. a sham control.

Countries Participating Austria, Belgium, France, Germany, Netherlands, United Kingdom.

Additional information and a list of participating clinical sites can be found at

RELIEF-1 Clinical Study (NCT02872298)

Patient Population Severe Asthma
Design This is a prospective, multi-center, single-arm (non-randomized) study.
Study Phase Phase 2
Study Goals The goal of the RELIEF-1 clinical study is to evaluate the safety and technical feasibility of Targeted Lung Denervation (TLD) for the treatment of severe asthma.
Countries Participating France, Germany, Netherlands, United Kingdom
Clinical Studies